Twin brothers cash in on anaphylaxis device

The twin brothers who founded Richmond, VA-based Intelliject to develop a better injection device for adrenaline, which is used to treat severe allergic reactions (anaphylaxis), licensed the technology to Sanofi-Aventis for $25 million and $208 million in milestones.

Evan and Eric Edwards knew from personal experience that the devices they used to inject adrenaline were bulky and could be hard to use. They came up with a device the size of a credit card which is equipped with a voice chip that can be used to explain how to use it.

"We expect to make an FDA submission some time early next year," Neil Hughes, vice president of marketing, told Richmond Biz Sense. "Once we make the submission, it is up to them how long it takes to approve it, which is usually about a year."

- check out Intelliject release
- read the story from Richmond Biz Sense

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.